skip to main content

GHS/HazCom Software Sale! Rules are changing—fall into compliance with these special offers. Learn More >

Back to search results

Streptococcus Agalactiae

Streptococcus Agalactiae

MATERIAL SAFETY DATA SHEET – INFECTIOUS SUBSTANCES

SECTION I – INFECTIOUS AGENT

NAME: Streptococcus agalactiae

SYNONYM OR CROSS REFERENCE: Group B streptococci

CHARACTERISTICS: Gram-positive cocci, ~2.0 µm occurring in pairs and short chains, facultatively anaerobic, beta hemolysis on blood agar

SECTION II – HEALTH HAZARD

PATHOGENICITY: Associated with diseases of the newborn; 90% of cases have septicemia, 40% have pulmonary involvement, and 30% have meningeal involvement; early onset disease acquired in utero or during passage through the birth canal and can have a case fatality rate of 50%; late onset disease with onset from 1 week to 3 months after birth have a case fatality rate of 20% and are probably acquired from the environment: survivors of meningitis cases can be left with hearing loss, blindness, cerebral palsy, mental retardation and/or epilepsy; adult infections include pneumonia, urinary tract infection, peritonitis, meningitis, endocarditis, osteomyelitis and rarely pharyngitis

EPIDEMIOLOGY: Worldwide; mainly causes diseases in infants <3 months of age with low birth weight and in the elderly; predispositions include diabetes mellitus, cancer, HIV

HOST RANGE: Humans, cattle (mastitis), other animals

INFECTIOUS DOSE: Not known

MODE OF TRANSMISSION: The manner of acquisition varies by age; 10-30% of pregnant women harbor Group B streptococci in the genital tract; approximately 1% of their offspring develop symptomatic infection within 6 days of birth; source of infection in older infants, children and adults are not well established

INCUBATION PERIOD: One to seven days for early onset disease, seven days to months for late onset disease

COMMUNICABILITY: Humans carry organisms in throat and vagina; attempts to eradicate genital tract group B streptococci in women during pregnancy with oral antibiotics only partially successful due to reinfection from rectal carriage of the organism or by reacquisition from culture-positive sexual partners

SECTION III – DISSEMINATION

RESERVOIR: Humans, cattle, horses, dogs, rabbits, guinea pigs, mice

ZOONOSIS: Possibly through direct or indirect contact with infected animals (mostly livestock workers); strains causing disease in humans are usually biochemically, metabolically or serologically different than those causing disease in animals; if animal transmission to humans does occur it is rare and of little significance

VECTORS: None

SECTION IV – VIABILITY

DRUG SUSCEPTIBILITY: Sensitive to penicillin or ampicillin; some strains penicillin tolerant and require treatment with an aminoglycoside as well

SUSCEPTIBILITY TO DISINFECTANTS: Susceptible to many disinfectants – 1% sodium hypochlorite and 70% ethanol, formaldehyde, glutaraldehyde, iodines

PHYSICAL INACTIVATION: Sensitive to moist heat (121° C for at least 15 min) and dry heat (160-170° C for at least 1 hour)

SURVIVAL OUTSIDE HOST: Dust – 20 to 30 days; contaminated cows feces – 21-63 days; litter – 20-30 days; paper contaminated with infected milk 4 days; urine 2-6 days; wood – 11 days

SECTION V – MEDICAL

SURVEILLANCE: Monitor for symptoms; confirm bacteriologically

FIRST AID/TREATMENT: Antibiotic therapy

IMMUNIZATION: None available

PROPHYLAXIS: Administration of penicillin or ampicillin at the onset and throughout labor to women who are colonized with group B and who are at high risk of delivering an infected infant (premature)

SECTION VI – LABORATORY HAZARDS

LABORATORY-ACQUIRED INFECTIONS: 78 recorded cases of Streptococcus spp. up to 1976

SOURCES/SPECIMENS: Blood, genital specimens, feces, urine, throat swabs and respiratory specimens

PRIMARY HAZARDS: Accidental parenteral inoculation; ingestion: inhalation of infectious aerosols, direct contact

SPECIAL HAZARDS: None

SECTION VII – RECOMMENDED PRECAUTIONS

CONTAINMENT REQUIREMENTS: Biosafety level 2 practices, containment equipment and facilities for all activities involving known or potentially infected clinical materials or culture; animal biosafety level 2 facilities for studies utilizing infected animals

PROTECTIVE CLOTHING: Laboratory coat; gloves when contact with infectious materials in unavoidable

OTHER PRECAUTIONS: None

SECTION VIII – HANDLING INFORMATION

SPILLS: Allow aerosols to settle; wearing protective clothing, gently cover spill with absorbent paper towel and apply 1% sodium hypochlorite, starting at perimeter and working towards the centre; allow sufficient contact time (30 min) before clean up

DISPOSAL: Decontaminate before disposal; steam sterilization, chemical disinfection, incineration

STORAGE: In sealed containers that are appropriately labelled

SECTION IX – MISCELLANEOUS INFORMATION

Date prepared: April, 2001

Prepared by: Office of Laboratory Security, PHAC

Although the information, opinions and recommendations contained in this Material Safety Data Sheet are compiled from sources believed to be reliable, we accept no responsibility for the accuracy, sufficiency, or reliability or for any loss or injury resulting from the use of the information. Newly discovered hazards are frequent and this information may not be completely up to date.

Copyright © Health Canada, 2001

This MSDS / PSDS document, provided by Public Health Agency of Canada (PHAC), is offered here as a FREE public service to visitors of www.EHS.com. As outlined in this site’s Terms of Use, VelocityEHS is not responsible for the accuracy, content or any aspect of the information contained therein.


Need an SDS? Search our entire SDS database containing millions of documents.